Mgi Tech Co.,Ltd. (688114.SH) climbed more than 8% in afternoon trading, last up 7.36% at 58.37 yuan with turnover reaching 381 million yuan.

On September 11, the full-stack life science tools provider announced a strategic collaboration with Baidu BioGene, a global leader in foundational models for life sciences. Together, they will build dedicated cellular large models tailored to specific clients and research scenarios, using these as the foundation to develop high-quality data production infrastructure for virtual cells and virtual perturbation experiments.

This alliance between an AI4S infrastructure leader and a top-tier AI4S model developer targets the industry's most scarce resource: high-quality data production capacity. Notably, high-quality experimental data serves as the most critical "fuel" for large models, and the ability to scale such data output has long been a core asset cultivated by Mgi Tech Co.,Ltd. over years of operation.

For Mgi Tech Co.,Ltd., this partnership signifies that its full-stack toolchain once again anchors cutting-edge research infrastructure. Its cross-omics instruments and experimental systems not only complete one-off experimental validation but also, through repeated verification, accumulate high-quality real-world data at scale, which in turn refines model iteration.

Looking ahead, both parties will work to standardize and productize their joint capabilities, exploring integrated "equipment plus model plus intelligent agent" solutions and AI CRO collaboration models.